Embecta Corp
EMBC Small CapHealthcare · Medical Instruments & Supplies
Updated: Aug 20, 2026, 22:20 UTC
Price Chart
Key Metrics
Valuation Analysis
About the Company
Embecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. It primarily sells its products to wholesalers and distributors. The company was formerly known as Berra Newco, Inc. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.
Embecta Corp Stock at a Glance
Embecta Corp (EMBC) is currently trading at $5.47 with a market capitalization of $309.9M. The trailing P/E ratio stands at 3.72x, with a forward P/E of 3.1x. The 52-week range spans from $2.77 to $15.55; the current price is 64.8% below the yearly high. Year-over-year revenue growth stands at -8.1%. The net profit margin stands at 8.59%.
💰 Dividend
Embecta Corp pays an annual dividend of $0.04 per share, representing a yield of 0.73%. The payout ratio stands at 31.29%.
📊 Analyst Rating
2 analysts rate Embecta Corp (EMBC) on consensus: Hold. The average price target is $4.00, implying -26.87% from the current price. Analyst price targets range from $3.00 to $5.00.
Embecta Corp: The Investment Case in Detail
Embecta Corp (EMBC) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
The Bull Case
The combination of a 58.42% gross margin and 23.67% operating margin shows the business converts revenue into profit efficiently — a hallmark of competitive moat. Our valuation screen flags the stock as undervalued relative to its fundamentals — multiples are running below where the cash flow profile would normally justify.
The Bear Case
Revenue is contracting at -8.1% year-over-year — until that trend reverses, valuation is exposed to further downgrades. Short interest sits at 14.18% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.
Valuation in Context
The EV/EBITDA multiple of 5.66x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
What to Watch Next
- The forward P/E of 3.1x is meaningfully below the trailing 3.72x — analysts expect earnings to step up; the next earnings release is the test.
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
Investment Thesis: Strengths & Weaknesses
- High gross margin of 58.42% — indicates pricing power
- Currently flagged as undervalued
- Positive free cash flow
- –Revenue shrinking (-8.1% YoY)
- –High short interest (14.18%)
Technical Snapshot
The price is in a transition zone relative to the moving averages — no clear signal.
Risk Profile
The data points to relatively defensive market behavior, elevated short interest (14.18%).
Trading Data
💵 Dividend Info
Related Stocks in the Same Sector
Embecta at 3.14 dollars: the BD-spinoff diabetes-pen-needle stock paying 14.6 percent dividend
The Real Story
Embecta makes the pen needles, syringes, and safety injection devices for diabetics. It is the global market leader in pen needles — the disposable tips that screw onto insulin pens — with 30+ percent share. Spun off from Becton Dickinson (BDX) in 2022 with about 1.6 billion USD of debt to bring back to BDX as part of the separation, Embecta has been a deleveraging story ever since.
The market hates Embecta because of one thing: Ozempic and GLP-1 drugs. As more diabetics shift from insulin therapy to weekly GLP-1 injections, demand for daily pen needles is theoretically threatened. The market has compressed EMBC to a 1.5x forward P/E and a 14.6 percent dividend yield — pricing in either a complete collapse or near-term equity wipeout. Reality is more nuanced: Type 1 diabetics still need daily insulin (GLP-1s do not replace insulin), and Type 2 diabetics on insulin do not all switch to GLP-1 immediately.
What Smart Money Thinks
Vanguard and BlackRock are passive holders. No major activist. Some deep-value funds added during the 2024 selloff. Insider buying has been modest.
Explore the BMI Smart-Money Tracker →
📈 The 3 Real Bull Points
📉 The 3 Real Bear Points
Valuation in Context
At 3.14 USD with 1.89 USD EPS the trailing P/E is 1.66 and forward P/E 1.56 — extreme. P/B is negative due to spinoff debt structure. EV/EBITDA 4.1 is half the medical-supplies sector median. The market is pricing in either a 50 percent EBITDA decline or a dividend cut. If neither happens, the stock doubles or triples on re-rate.
🗓️ Next 3 Catalyst Dates
- :
- :
- :
💬 Daniel's Take
EMBC is a special-situation deep-value bet on the proposition that GLP-1 fear is overstated and the dividend is sustainable. Forward P/E 1.56 is the lowest in medical devices. The risk is dividend cut and continued GLP-1 erosion; the reward is multiple expansion plus dividend income. I would size 0.5 to 1 percent in a special-situations sleeve — small because of the binary dividend risk. The 14.6 percent yield only matters if you believe it survives.
Sources (3)
Disclaimer: This article is not investment advice. Investing in stocks carries risks, including total loss.
More Healthcare stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Embecta Corp?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
📊 Prefer a fund over a single stock? Compare ETFs:
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news